Arix Bioscience PLC (LON:ARIX) has noted portfolio company LogicBio Therapeutics’ (Nasdaq:LOGC) approval for a Phase 1/2 clinical trial of its LB-001 programme for very young children with methylmalonic acidemia (MMA) .

LogicBio said it expects patient enrolment to begin in early 2021.

“We’re pleased to announce our plans for developing LB-001 in pediatric patients with MMA,” said Fred Chereau, CEO of LogicBio.

“This is an important milestone for patients, their families, our company and for the genetic medicines space more broadly as we believe this is the first Investigational New Drug application (IND) clearance for an in vivo gene editing program harnessing homologous recombination,”